Wellington Partners
Wellington Partners today announced the final close of its fifth-generation fund Wellington Partners Life Science Fund V (WPLS-V). The fund closed at EUR 210 million, making it the largest life science dedicated fund raised by Wellington Partners to date. WPLS-V will build a portfolio of approximately 15-20 companies, ranging in focus from novel biotechnology platforms, new therapeutics and medical devices, including selected investments in diagnostics and digital medicine. All of the fund’s investments will target substantial improvements to current medical practice for the benefit of patients, practitioners, and payors alike.
Quanta Dialysis Technologies today announces that it has successfully raised £38 million ($48 million) in a first closing of its Series C funding round. The round was led by a Swiss private family office in combination with btov Partners and co-led by Wellington Partners and Seroba Life Sciences, along with participation from other existing investors. Proceeds will be used to fund the UK commercial launch of SC+ and a 510(k) submission to the FDA later this year.
Immatics today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO). Harpreet Singh has most recently been President and CEO of Immatics US and Chief Scientific Officer (CSO) of the Company, having co-founded Immatics. He has been instrumental in growing the Company from a start-up to a leading player in the field of immuno-oncology.
Page 1 of 20
